# A Safety Study of Tucatinib in Healthy and Hepatically-Impaired Subjects

> **NCT03722823** · PHASE1 · COMPLETED · sponsor: **Seagen Inc.** · enrollment: 37 (actual)

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** Tucatinib

## Key facts

- **NCT ID:** NCT03722823
- **Lead sponsor:** Seagen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-10
- **Primary completion:** 2019-05-07
- **Final completion:** 2019-05-07
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2019-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03722823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03722823, "A Safety Study of Tucatinib in Healthy and Hepatically-Impaired Subjects". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03722823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*